Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 7/20 | 0.34 |
| ▸ | BRAF | P15056 | 7/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | CDK8 | P49336 | 1/20 | 0.33 |
| ▸ | GSK3A | P49840 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | CDK9 | P50750 | 1/20 | 0.33 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.33 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.33 |
| ▸ | RAF1 | P04049 | 1/20 | 0.32 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3660164 | 0.88 | CSF1R (0.42) | KDR | |
| SCHEMBL5068791 | 0.88 | KDR (0.41) | RXRAGRIN1GRIN2BROCK2KDR | |
| SCHEMBL5067406 | 0.86 | RXRA (0.37) | RXRAGRIN1GRIN2BROCK2ROCK1 | |
| SCHEMBL3797031 | 0.86 | RXRA (0.36) | RXRAGRIN1GRIN2BROCK2ROCK1 | |
| SCHEMBL3807000 | 0.83 | BRAF (0.51) | BRAFMAPK13MAPK14 | |
| SCHEMBL3666718 | 0.81 | MAPK14 (0.49) | ROCK2ROCK1KDRBRAFRAF1 | |
| SCHEMBL5064093 | 0.80 | MAPK14 (0.38) | RXRAGRIN1GRIN2BROCK2ROCK1 | |
| SCHEMBL3661974 | 0.79 | KDR (0.41) | RXRAGRIN1GRIN2BROCK2ROCK1 | |
| SCHEMBL5063126 | 0.76 | BRAF (0.46) | BRAFMAPK14 | |
| SCHEMBL3662665 | 0.76 | CSF1R (0.42) | KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269254-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFIC DISEASES AND OTHER PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269254-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFIC DISEASES AND OTHER PROLIFERATIVE DISEASES | KIT, BRAF, RET | RXRA 3067/4885GRIN1 3171/4885GRIN2B 2987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.